In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reckitt Begins CEO Search As Kapoor Departs The Company He Reshaped

Executive Summary

Reckitt Benckiser's long-serving CEO, Rakesh Kapoor, has unexpectedly announced his intention to retire by the end of the year, with the company immediately kicking off the search for his replacement. Kapoor will be remembered for transforming RB's consumer health business, but also for a number of setbacks under his watch which have impacted results.

You may also be interested in...



Reckitt Names New CEO To Ignite Growth And Lead Digital Transformation

Reckitt Benckiser has poached PepsiCo's global chief commercial officer, Laxman Narasimhan, to replace Rakesh Kapoor as the UK-based firm's CEO. Setting his stall out early, Narasimhan has made clear that RB's "capabilities and culture" need to change to make the company fit for the new digital world.

Reckitt ‘Not Happy’ With Consumer Health Growth In 2018, Following European And Infant Nutrition Woes

RB's Health business failed to keep pace with market growth in 2018, with the firm admitting its mindset in Europe "needs to change." The UK-based consumer-goods giant spent the 12 months working on its RB 2.0 restructuring program, which will give it the option to separate into two independent companies focusing on Health and Hygiene by 2020.

GSK And Pfizer Start Consumer JV For Different Reasons, Aim For Similar Goals

Big pharmas' agreement could put consumer health where Pfizer wants, entirely in its rear-view mirror, and points GSK toward what it wants, more research and development funding freed up for the pharmaceutical ingredient operations that are its chief revenue drivers. All-equity deal, giving GSK 68% control and expected to close in 2019 second half, also likely will boost investors' confidence in the firms as both have been dogged by pressure to sell, spin-off or otherwise divest their consumer businesses.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel